Abstract: The co-occurrence network revealed that the major resistance pathways N155H and Q148HR share more mutations with each other than with the Y143R pathway, this observation corroborates the fact that the N155H pathway is most commonly converted into Q148HRK than into Y143RCH pathway in patients' isolates.
Introduction: In the early stages of therapy, the mutation N155H tends to appear and can be later substituted by either the Y143R or Q148HKR pathway after prolonged treatment.
Result: This is in agreement with the fact that resistance pathways are mutually exclusive, and the N155H pat
Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations.
PMID: 31611362
2019
Antimicrobial agents and chemotherapy
Abstract: In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q148H/K/R plus one to two additional INSTI mutations.
Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing.
PMID: 29873733
2018
The Journal of antimicrobial chemotherapy
Abstract: Among 53 patients harbouring at least one resistance mutation detected by both techniques, the most dominant INSTI resistance mutations were N155H (45%), Q148H/K/R (23%), T97A (19%) and Y143C (11%).
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus.
PMID: 29077927
2018
The Journal of antimicrobial chemotherapy
Abstract: A higher risk of VF was independently associated with baseline viral load >100000 copies/mL (adjusted HR = 4.73, 95% CI = 1.33-16.78, P = 0.016) and with >=1 INSTI mutations plus Q148H/K/R/N and the G140S/A/C as compared with other subjects (adjusted HR = 4.18, 95% CI = 1.32-13.23, P = 0.015).
Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.
Method: For CAB, the presence of E138A/Q148R, E138K/Q148K, E138K/Q148R, G140C/Q148R, G140S/Q148R, or Q148R/N155H was interpreted as high-level resistance.
Result: Five patients (21%) with multiple mutations (Q148QR+N155H, G140A+Q148R, E138K+G140S+Q148R, E138K+ PMID: 29304821
2018
Retrovirology
Introduction: For instance, raltegravir resistance mutations Q148H/K/R and N155H show a high level of cross-resistance with elvitegravir, but elvitegravir susceptibility is unaffected by Y143 mutations, a difference that is beautifully explained by crystal structures of the intasome in presence of raltegravir or elvitegravir.
Introduction: Resistance is commonly associated with selection of one of the signature raltegravir resistance mutations Y143C/R/H, Q148H/K/R or N155H.
Introduction: The resistance patterns observed in HIV-1 patients on a raltegravir containing regimen are very diverse and Q148H/K/R (usually with G140A/C/S and/or E138A/K
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Abstract: However, three CAB selections resulted in Q148R/K followed by secondary mutations conferring high-level cross-resistance to all INSTIs.
Abstract: The development of Q148R/K with CAB can result in high-level cross-resistance to all INSTIs.
Result: For isolate 5326, the progressive accumulation of Q148K/G140S/G147GS resulted in increasingly high cross-resistance to CAB, RAL and EVG while retaining susceptibility to DTG and BIC (Table 3).
Result: For the remaining seven isolates, CAB showed a lower barrier to resistance than DTG and BIC, with the acquisition of Q148R/K + 3 mutations in two isolates (Table 3).
Result: In contrast, the respective first
Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
Result: Most of the minority mutations in viruses from both groups of naive patients were observed in the RT, e.g., M41L, E44D, A62V, K65R, D67N, D67G, V75I, L100I, K103N, K103R, V188I, M184I, L210W, K219Q, Y318F, etc., although a number of minority mutations associated with resistance to PI (L10F, V11I, M46I/
Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes.
PMID: 27993614
2017
Journal of virological methods
Abstract: Mutations associated with integrase resistance were observed in seven of the 106 (7%) clinical samples [one sample: Q148K; E138K; G140A; two samples: T97A and four samples: L74I].
Result: The following mutations were observed: Q148K; E138K; G140A in one sample; T97A in two samples; and L74I in four samples.
Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
PMID: 28369593
2017
The Journal of antimicrobial chemotherapy
Abstract: Although dolutegravir may allow successful rescue in most HIV-2 raltegravir failures, we report and characterize three cases of dolutegravir resistance in HIV-2 patients, emerging variants Q148K and Q148R and a novel change G118R.
Abstract: In two of them N155H was replaced by Q148K/R and in another by G118R.
HIV mutation literature information.
PMID: 
2019
Frontiers in microbiology
Browser Board
Co-occurred Entities
Filtrator
ViMRT